← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,159	+24	+2%	$59B
2	2 Danaher DHR $158B	1,129	+2	+0.2%	$45B
3	3 Novartis NVS $279B	921	+11	+1%	$21.7B
4	4 Regeneron Pharmaceuticals REGN $80.1B	604	+25	+4%	$35.9B
5	5 Agilent Technologies A $49.1B	589	+37	+7%	$16.4B
6	6 Illumina ILMN $41B	564	+34	+6%	$23.8B
7	7 Revvity RVTY $17B	340	+30	+10%	$6.92B
8	8 Charles River Laboratories CRL $14.4B	302	+2	+0.7%	$4.65B
9	9 Ionis Pharmaceuticals IONS $7.1B	294	+23	+8%	$5.68B
10	10 DELISTED bluebird bio BLUE	241	+31	+15%	$5.17B
11	11 DELISTED CATALENT, INC. CTLT	241	+32	+15%	$4.43B
12	12 Myriad Genetics MYGN $397M	239	+6	+3%	$2.12B
13	13 Alnylam Pharmaceuticals ALNY $30B	227	+28	+14%	$6.95B
14	14 Azenta AZTA $1.63B	222	+26	+13%	$1.4B
15	15 Qiagen QGEN $9.41B	211	+28	+15%	$4.77B
16	16 Bruker BRKR $8.47B	200	-2	-1%	$3.05B
17	17 Sarepta Therapeutics SRPT $1.78B	190	+10	+6%	$1.44B
18	18 Precigen PGEN $2.63B	172	+18	+12%	$2.41B
19	19 Ultragenyx Pharmaceutical RARE $1.47B	159	-6	-4%	$2.56B
20	20 DELISTED SANGAMO THERAPEUTICS INC SGMO	143	+25	+21%	$467M
21	21 PTC Therapeutics PTCT $4.98B	114	-1	-0.9%	$615M
22	SIOX 22 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	113	+16	+16%	$2.52B
23	23 Editas Medicine EDIT $349M	110	+11	+11%	$490M
24	24 Lineage Cell Therapeutics LCTX $232M	109	+13	+14%	$151M
25	25 Pacific Biosciences PACB $619M	107	+1	+0.9%	$281M